Takeda’s Derek Wallace discussed the thorough process of developing the dengue vaccine, which they are calling TAK- 003. According to the New England Journal of Medicine, TAK- 003 is 80% effective in preventing people from getting dengue and 95% effective in preventing hospitalizations associated with dengue fever.Even though the company claims that the vaccine, TAK- 003, will bring about a major development in the fight against dengue, they still have a long way to go. Stephen Waterman, the head of US Centres for Disease Control and Prevention’s Dengue Branch, also got in talks with NPR and expressed that a full trial data of the study over a longer period of time is required to be sure of the vaccine’s efficacy rates. Waterman was also a part of the study conducted by Takeda. To be even more accurate, the company’s officials have decided to keep the study going by checking on the participants of TAK- 003’s development study for some more years, according to NPR reports.